PRO DEX INC (PDEX) stock intrinsic value fair value estimate & owner earnings analysis

Pro-Dex designs and makes powered surgical handpieces (drivers and shavers) for orthopedic, craniomaxillofacial and thoracic surgery, mostly under exclusive development and supply agreements with large device companies that sell them under their own brands. Fiscal 2026 (year to June 30, 2026) revenue was $77.5 million, up 16%, with operating income of $13.0 million. Net income of $13.7 million included $5.7 million of net gains on equity investments, led by a $9.1 million realized gain when Zimmer Biomet bought Monogram Technologies. We leave investment gains and losses out of earnings and count the sale proceeds only as cash. What has changed: our earlier write-up described the main supply agreement as running only through calendar 2025. In the second quarter of fiscal 2026 the largest customer extended it through calendar 2028, with higher volumes of its newest handpiece. In February 2026 Pro-Dex also bought APM, a Costa Mesa, California machine shop that had been a significant supplier, for $6.5 million in cash plus a $2.0 million seller note. Our earlier values were built on a different basis and are not comparable with these. The dominant risk is concentration. One customer was 78% of fiscal 2026 sales and the top three were 92%. That customer is committed to buy through 2028 and has placed orders for 2027; nothing is committed after that. The company's own record cuts both ways. In fiscal 2015 its then-largest customer bought $6.6 million (55% of sales); after that customer began making the product itself, purchases fell to $3.6 million in fiscal 2016 and $1.5 million in fiscal 2017, and Pro-Dex had pre-tax losses in fiscal 2013 through 2015. On the other hand, the current largest customer's purchase commitments have been extended again and again: through calendar 2018 (disclosed in fiscal 2017), through 2025 (amended in fiscal 2021, the same year a development agreement was signed for the next-generation handpiece) and now through 2028. The next-generation handpiece launched in fiscal 2025, and in the third quarter of that year the customer briefly asked Pro-Dex to hold its shipments before asking it to resume. Earnings level. We measure cash earnings as operating cash flow, less swings in receivables, inventory and other working capital, less stock compensation, less the capital spending needed to maintain the plant, and then add back interest paid so the business can be valued before its lenders. On that basis the last three years were $5.6 million, $8.2 million and $10.2 million (fiscal 2024, 2025, 2026). We use the middle figure, $8.2 million (about $2.48 a share on 3.29 million diluted shares), as the normal level; earlier years describe a much smaller company, and fiscal 2021 included a one-time $6.5 million purchase of a building. This is deliberately 20% below fiscal 2026: repair revenue fell 33% to $12.5 million as the customer moves off the legacy handpiece and may keep falling (billable repairs on the new handpiece start in fiscal 2027 at volumes the company does not yet know), and backlog at June 30 was $32.9 million against $50.4 million a year earlier, which management attributes to timing. Cash earnings grew about 25% in fiscal 2026; our base case assumes no growth in year 1, which is below that trailing rate. Three accounting judgements matter: working-capital swings are excluded, so the measure is only valid for a business that is not growing (this company absorbed about $31 million of working capital over the last ten years, $10.5 million in fiscal 2025 alone, and held $21.5 million of inventory and $21.2 million of receivables at June 30, 2026, which is why we credit no growth); stock compensation of $0.7 million is treated as a real cost; and fiscal 2026 capital spending of $0.5 million was unusually low, which is another reason we use the median year rather than the latest. What the business owes. Borrowings were $17.5 million at June 30, 2026 (bank term loans and a property loan at 3.55% to 5% or a floor rate, a revolver, and the 8% seller note), plus roughly $0.75 million of equipment finance leases acquired with APM (our estimate from the lease schedule). Against that, cash was $8.2 million and marketable investments $1.15 million, less $0.9 million paid in July 2026 for employee taxes on vested stock awards. Net debt is about $9.8 million, or about $2.99 a share. $11.0 million was available under the revolver, which matures December 29, 2027; principal of $4.2 million falls due in fiscal 2027 and $3.6 million in fiscal 2028, and the property loan has a $3.1 million balloon in November 2030. The company says it is in compliance with its covenants, and its credit agreements prohibit dividends. Base case, $20.29 a share: the business is worth about $76.7 million ($23.28 a share) and owes about $9.8 million ($2.99 a share). Cash earnings stay at $8.2 million a year through fiscal 2036 with no growth, on the view that the largest customer renews after 2028 as it has twice before and sells the co-developed next-generation handpiece, whose predecessor was already generating $10.9 million of sales to the largest customer in fiscal 2017. After fiscal 2036 nothing we can name guarantees the relationship, so earnings fade in a straight line to zero by fiscal 2046. Growth credited: none. Left out because it has not happened or is not proven: thoracic and CMF growth (thoracic sales fell to $2.1 million), APM's defense and aerospace work, repair volumes on the new handpiece, improved plant absorption ($1.9 million of under-absorbed overhead in fiscal 2026), further acquisitions, and Monogram's four remaining milestone payments. Bear case, $9.35 a share: the business is worth about $40.7 million ($12.34 a share) and owes about $9.8 million, a difference of $9.35 a share. The contract is honored through December 2028 but legacy repair erosion takes cash earnings to $6.5 million in fiscal 2027 and 2028. After 2028 the largest customer repeats the fiscal 2015 to 2017 episode: purchases fall 45% in the first year and 77% by the second, with $1.0 million a year of stranded costs for two years (cash earnings $4.7 million in fiscal 2029 and $2.8 million in fiscal 2030). The business then settles at $3.8 million a year: about $3.0 million from everything else (fiscal 2017 to 2019 delivered $2.7 million to $4.6 million on $22 million to $27 million of revenue) plus the 23% of the largest customer's contribution that survived last time. That holds through fiscal 2036 and fades to zero by fiscal 2046. Even then cash earnings stay well above the interest bill of about $0.8 million, so the debt is carried. We did not add a separate elective-surgery downturn because the 2020 shutdown year did not hurt this business (fiscal 2020 revenue rose 28% and operating income rose from $5.0 million to $7.1 million); the customer, not the cycle, is the named risk. Bull case, $28.86 a share: the business is worth about $104.9 million ($31.85 a share) and owes about $9.8 million. Cash earnings hold at the fiscal 2026 level of $10.2 million through fiscal 2036, which requires the new handpiece's repair work to replace the legacy repair revenue now being lost and the customer to renew after 2028, then fade to zero by fiscal 2051 on the evidence that this customer has bought a Pro-Dex handpiece for at least a decade and co-developed a successor. No growth is assumed. What would make this wrong. Each $1 million a year of lasting change in cash earnings moves the base value by roughly $2.90 a share. The largest swing factor is the post-2028 renewal: if it fails, value moves toward the bear figure. A repair decline faster than we assume, or a pause in shipments like the one in fiscal 2025, would lower the near-term level. Higher maintenance spending than the median year would also lower it. If the customer renews on larger volumes, value would move toward the bull figure. We could not separate the cash tax paid on the Monogram gain from ordinary taxes ($4.1 million of income taxes were paid in fiscal 2026), so fiscal 2026 cash earnings may be slightly understated. How we reached the margin-of-safety price. We are reasonably sure of the last three years of audited cash, but less sure the level survives 2028 because 78% of sales depend on one customer with a record to our knowledge of both renewing and, for an earlier product, bringing production in-house. The worst plausible outcome is a customer exit or sharp cut earlier or deeper than the bear case, against a cost base that grew in fiscal 2026 (general and administrative expense rose 55% to $7.5 million). The balance sheet should survive that: debt is modest against the cash on hand, a large revolver is available, the Irvine facility is owned subject to the property loan, and $42.7 million of inventory and receivables would partly turn to cash, though we do not count on it. If we are wrong on the renewal the shares are worth about the bear figure; if we are wrong on repair erosion the base figure is too high by about $3 a share for each $1 million of lost annual cash earnings; if capital spending reverts to its ten-year average of about 2.8% of revenue the level is lower. The price assumes a holding period lasting at least until the 2028 renewal is settled, roughly two years. During that period the company pays no dividend, but it uses its cash to repay debt (about $8 million of principal over fiscal 2027 and 2028) and has repurchased shares every year ($3.4 million in fiscal 2026). The margin-of-safety price is $10.00. From that price the base case implies about 20% a year over five years (more if the renewal is settled sooner), and the bear case implies roughly recovering the price with a small return. A higher price leaves too little protection in the bear path given how much rides on a single contract.